Skip to Main Content
Back to News

Lobbying Update: $60,000 of JOHNSON & JOHNSON SERVICES INC lobbying was just disclosed

None

$60,000 of JOHNSON & JOHNSON SERVICES INC lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Issues related to appropriations, animal welfare, and health policy. Issues related to appropriations, animal welfare, and health policy."

You can find more data on corporate lobbying on Quiver Quantitative.

JNJ Congressional Stock Trading

Members of Congress have traded $JNJ stock 16 times in the past 6 months. Of those trades, 5 have been purchases and 11 have been sales.

Here’s a breakdown of recent trading of $JNJ stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

JNJ Insider Trading Activity

JNJ Insider Trades

JNJ insiders have traded $JNJ stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $JNJ stock by insiders over the last 6 months:

  • JOAQUIN DUATO (CEO and Chairman of the Board) sold 125,824 shares for an estimated $22,548,654
  • JENNIFER L TAUBERT (EVP, WWC. Innovative Medicine) sold 56,471 shares for an estimated $10,040,882
  • JOHN C REED (EVP, Innovative Medicine, R&D) sold 19,137 shares for an estimated $3,129,829
  • JOSEPH J WOLK (Exec VP, CFO) sold 16,820 shares for an estimated $2,975,570

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

JNJ Hedge Fund Activity

We have seen 1,705 institutional investors add shares of JNJ stock to their portfolio, and 2,039 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

JNJ Analyst Ratings

Wall Street analysts have issued reports on $JNJ in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • Wells Fargo issued a "Overweight" rating on 10/03/2025
  • Citigroup issued a "Buy" rating on 08/21/2025
  • RBC Capital issued a "Outperform" rating on 07/17/2025
  • UBS issued a "Buy" rating on 07/17/2025
  • Raymond James issued a "Outperform" rating on 04/16/2025

To track analyst ratings and price targets for JNJ, check out Quiver Quantitative's $JNJ forecast page.

JNJ Price Targets

Multiple analysts have issued price targets for $JNJ recently. We have seen 12 analysts offer price targets for $JNJ in the last 6 months, with a median target of $191.5.

Here are some recent targets:

  • Lee Hambright from Bernstein set a target price of $193.0 on 10/06/2025
  • Tim Anderson from B of A Securities set a target price of $198.0 on 10/03/2025
  • Larry Biegelsen from Wells Fargo set a target price of $212.0 on 10/03/2025
  • Vamil Divan from Guggenheim set a target price of $206.0 on 09/23/2025
  • Michael Weinstein from JP Morgan set a target price of $200.0 on 09/16/2025
  • Joanne Wuensch from Citigroup set a target price of $200.0 on 08/21/2025
  • Terence Flynn from Morgan Stanley set a target price of $176.0 on 07/17/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles